Authorization

Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society

POXEL
S.A. (Euronext a?? POXEL - FR0012432516), a biopharmaceutical company
focused on the development of innovative treatments for metabolic
disorders, including type 2 diabetes and non-alcoholic steatohepatitis
(NASH), announced today that it will be featured as a presenting company
at the Jefferies 2019 Global Healthcare Conference and the JMP
Securities Life Sciences Conference. In addition, Imeglimin will be
discussed during a symposium at the 62nd Annual Meeting of
the Japanese Diabetes Society.





The 62nd Annual Meeting of the Japanese Diabetes Society is
being held on May 23-25, 2019 at the Sendai International Center,
Sendai, Japan. Imeglimin will be discussed in Featured Symposium #4 on
New Mode of Action Drugs to Clinical on Thursday, May 23rd,
2019 from 2:30-5:00 PM JST.






The Jefferies 2019 Global Healthcare Conference is being heldA on June
4-7, 2019 at The Grand Hyatt Hotel in New York City. The Company will
present a corporate overview on Wednesday, June 5th from
10:30-10:55 AM EDT and will be available to participate in one-on-one
meetings with investors. The presentation will be webcast live. To
access the webcast, please visit the following link https://wsw.com/webcast/jeff118/poxel.pa/.
The webcast replay will remain available for 90 days following the
live presentation.






The JMP Securities Healthcare Conference is being held on June 19-20,
2019 at the St. Regis Hotel in New York City. The Company will
present a corporate overview on Wednesday, June 19th from
11:30-11:55 AM EDT and will be available to participate in one-on-one
meetings with investors.





About Poxel SA


Poxel uses its development expertise in metabolism to advance a pipeline
of drug candidates focused on the treatment of metabolic disorders,
including type 2 diabetes and non-alcoholic steatohepatitis (NASH). We
have successfully completed the Phase 2 clinical program for our
first-in-class lead product, Imeglimin, which targets mitochondrial
dysfunction, in the U.S., Europe and Japan. Together with our partner
Sumitomo Dainippon Pharma, we are conducting the Phase 3 Trials
of IMeglimin for Efficacy and Safety (TIMES)
program for the treatment of type 2 diabetes in Japan. Our partner
Roivant Sciences is responsible for Imeglimina??s development and
commercialization in countries outside of Poxela??s partnership with
Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a
first-in-class direct adenosine monophosphate-activated protein kinase
(AMPK) activator, is in a Phase 2a proof-of-concept program for the
treatment of NASH. PXL770 could also have the potential to treat
additional metabolic diseases. PXL065 (deuterium-stabilized
R-pioglitazone), a mitochondrial pyruvate carrier (MPC) inhibitor, is in
Phase 1 and being developed for the treatment of NASH. Poxel also has
additional earlier-stage programs, including deuterated drug candidates
for metabolic, specialty and rare diseases. We intend to generate
further growth through strategic partnerships and pipeline development.
(Euronext: POXEL,A www.poxelpharma.com)



Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005427/en/
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Декабрь 2019    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
3031